B. Rowley

发表

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.

Syk tyrosine kinase required for mouse viability and B-cell development

Tony Pawson, William Pao, Adrian Hayday, 1995, Nature.

Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor

D. Auclair, P. Vincent, G. Bollag, 2004 .

Homoisocitric dehydrogenase from yeast.

B. Rowley, A. Tucci, 1970, Archives of biochemistry and biophysics.

Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.

T. Pawson, W. Pao, A. Hayday, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Elemental (XRF), Mineralogical (XRD), and Organic Geochemical (programmed pyrolysis) Analyses Used to Determine the Contribution of Reservoir Quality to Differential Wellbore Production of Single-Pad, Multi-Lateral Wells in the Eagle Ford, South Texas, USA.

B. Rowley, M. Jaeger, C. C. Matson, 2015 .

Constitutively Active Insulin-Like Growth Factor I Receptor Tumor Development by Transgenic Expression of a

Adrian V. Lee, F. Lee, D. Bol, 2005 .

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

A. Haegebarth, S. Wilhelm, K. Ziegelbauer, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics BAY 80-6946 Is a Highly Selective Intravenous PI 3 K Inhibitor with Potent p 110 a and p 110 d Activities in Tumor Cell Lines and Xenograft Models

A. Haegebarth, S. Wilhelm, K. Ziegelbauer, 2013 .

A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera

J. Wood, M. Lynch, S. Linder, 2003, Apoptosis.

Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics

F. Lee, B. Fink, K. Kellar, 2006, Molecular Cancer Therapeutics.

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Adrian V. Lee, F. Lee, D. Bol, 2005, Cancer research.

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.